Novakand Pharma AB (publ) (STO:NOVKAN)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0401
-0.0049 (-10.89%)
At close: Mar 27, 2026
Market Cap4.86M -96.6%
Revenue (ttm)n/a
Net Income-47.23M
EPS-0.39
Shares Out121.19M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,728,972
Average Volume999,309
Open0.0450
Previous Close0.0450
Day's Range0.0400 - 0.0450
52-Week Range0.0356 - 2.2500
Beta0.92
RSI27.54
Earnings DateApr 24, 2026

About Novakand Pharma AB

Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in Septembe... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol NOVKAN
Full Company Profile

Financial Performance

Financial Statements